{"id":751720,"date":"2023-04-26T18:16:51","date_gmt":"2023-04-26T22:16:51","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/rapt-therapeutics-announces-flx475-poster-presentation-at-the-2023-american-society-of-clinical-oncology-asco-annual-meeting\/"},"modified":"2023-04-26T18:16:51","modified_gmt":"2023-04-26T22:16:51","slug":"rapt-therapeutics-announces-flx475-poster-presentation-at-the-2023-american-society-of-clinical-oncology-asco-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/rapt-therapeutics-announces-flx475-poster-presentation-at-the-2023-american-society-of-clinical-oncology-asco-annual-meeting\/","title":{"rendered":"RAPT Therapeutics Announces FLX475 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">SOUTH SAN FRANCISCO, Calif., April  26, 2023  (GLOBE NEWSWIRE) &#8212; RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced it will present a poster on FLX475, its lead oncology drug candidate, at the 2023 American Society of Clinical Oncology (ASCO) annual meeting taking place June 2-6, 2023 at the McCormick Place Convention Center in Chicago, IL.<\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td colspan=\"2\">Presentation details:<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td style=\"max-width:15%;width:15%;min-width:15%\">\n            <strong>Title:<\/strong>\n          <\/td>\n<td style=\"max-width:85%;width:85%;min-width:85%\">Clinical and Biological Activity of FLX475, an Oral CCR4 Antagonist, in Advanced Cancer<\/td>\n<\/tr>\n<tr>\n<td>\n            <strong>Session Title:<\/strong>\n          <\/td>\n<td>Developmental Therapeutics\u2014Immunotherapy<\/td>\n<\/tr>\n<tr>\n<td>\n            <strong>Session Date and Time:<\/strong>\n          <\/td>\n<td>Saturday, June 3, 2023; 8:00 a.m. &#8211; 11:00 a.m. ET<\/td>\n<\/tr>\n<tr>\n<td>\n            <strong>Abstract Number:<\/strong>\n          <\/td>\n<td>2625<\/td>\n<\/tr>\n<\/table>\n<p>The abstract will be released on Thursday, May 25, 2023 at 5:00 p.m. ET on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=X7IT0LNI5HHrJhIjGFtshbwdxvkXIydNqNGAUTHBx7yAdN-8xX4eK591qrKyp7boEFHuqoU1AjV2rp1HdBsRblCdV13LiLJEgvrF68QxCyda9zVYeTx5B8hVAhCNo4YKg-P9uqpO8662w5xvMwxYAI5wcBQDcefkvguuR7YLGhUr513boqIgmpT2vkLWx3nG\" rel=\"nofollow noopener\" target=\"_blank\">meetings.asco.org<\/a>.<\/p>\n<p>\n        <strong>About RAPT Therapeutics, Inc.<\/strong><br \/>\n        <br \/>RAPT Therapeutics is a clinical stage immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology. Utilizing its proprietary discovery and development engine, the company is developing highly selective small molecules designed to modulate the critical immune drivers underlying these diseases. RAPT has discovered and advanced two unique drug candidates, RPT193 and FLX475, each targeting C-C motif chemokine receptor 4 (CCR4), for the treatment of inflammation and cancer, respectively. The company is also pursuing a range of targets that are in the discovery stage of development.<\/p>\n<p>\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>Sylvia Wheeler<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=buul0It4WkNg1a8dS6SR1SGG6wpa4WE5teJpmXt1ybrQ4iX6GM3gZV2-mP_eLF3ZvSpUHVJbWo6cdWi86_WEXoCAtA-ccLMBDp_dnscB8gbCyPdc80lOohspSgScz55Z\" rel=\"nofollow noopener\" target=\"_blank\">swheeler@wheelhouselsa.com<\/a><\/p>\n<p>\n        <strong>Media Contact:<\/strong><br \/>\n        <br \/>Aljanae Reynolds<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=qGCUqHaRQr4QNyHVA6yQgjMldneH2Z3_YbNWvjTaonPPzcnG0_S9Qq_1OKECbrKG4vm5EusMG-w1l3CpGoGlSKmjLctgOJNsMREY-JYYAhcpsSxNf2FdaSp8eUqmvrlz\" rel=\"nofollow noopener\" target=\"_blank\">areynolds@wheelhouselsa.com<\/a><\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNjU0MyM1NTYwMDY2IzIwMjkyMDk=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/OTBhY2ZiMTQtMTdhYS00NjVlLTkxNDgtYzUwNjZmN2U5OTgzLTEwNDA3ODA=\/tiny\/RAPT-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SOUTH SAN FRANCISCO, Calif., April 26, 2023 (GLOBE NEWSWIRE) &#8212; RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced it will present a poster on FLX475, its lead oncology drug candidate, at the 2023 American Society of Clinical Oncology (ASCO) annual meeting taking place June 2-6, 2023 at the McCormick Place Convention Center in Chicago, IL. Presentation details: Title: Clinical and Biological Activity of FLX475, an Oral CCR4 Antagonist, in Advanced Cancer Session Title: Developmental Therapeutics\u2014Immunotherapy Session Date and Time: Saturday, June 3, 2023; 8:00 a.m. &#8211; 11:00 a.m. ET Abstract Number: 2625 The abstract will &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/rapt-therapeutics-announces-flx475-poster-presentation-at-the-2023-american-society-of-clinical-oncology-asco-annual-meeting\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;RAPT Therapeutics Announces FLX475 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-751720","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>RAPT Therapeutics Announces FLX475 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/rapt-therapeutics-announces-flx475-poster-presentation-at-the-2023-american-society-of-clinical-oncology-asco-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"RAPT Therapeutics Announces FLX475 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SOUTH SAN FRANCISCO, Calif., April 26, 2023 (GLOBE NEWSWIRE) &#8212; RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced it will present a poster on FLX475, its lead oncology drug candidate, at the 2023 American Society of Clinical Oncology (ASCO) annual meeting taking place June 2-6, 2023 at the McCormick Place Convention Center in Chicago, IL. Presentation details: Title: Clinical and Biological Activity of FLX475, an Oral CCR4 Antagonist, in Advanced Cancer Session Title: Developmental Therapeutics\u2014Immunotherapy Session Date and Time: Saturday, June 3, 2023; 8:00 a.m. &#8211; 11:00 a.m. ET Abstract Number: 2625 The abstract will &hellip; Continue reading &quot;RAPT Therapeutics Announces FLX475 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/rapt-therapeutics-announces-flx475-poster-presentation-at-the-2023-american-society-of-clinical-oncology-asco-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-26T22:16:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNjU0MyM1NTYwMDY2IzIwMjkyMDk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rapt-therapeutics-announces-flx475-poster-presentation-at-the-2023-american-society-of-clinical-oncology-asco-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rapt-therapeutics-announces-flx475-poster-presentation-at-the-2023-american-society-of-clinical-oncology-asco-annual-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"RAPT Therapeutics Announces FLX475 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting\",\"datePublished\":\"2023-04-26T22:16:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rapt-therapeutics-announces-flx475-poster-presentation-at-the-2023-american-society-of-clinical-oncology-asco-annual-meeting\\\/\"},\"wordCount\":260,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rapt-therapeutics-announces-flx475-poster-presentation-at-the-2023-american-society-of-clinical-oncology-asco-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNjU0MyM1NTYwMDY2IzIwMjkyMDk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rapt-therapeutics-announces-flx475-poster-presentation-at-the-2023-american-society-of-clinical-oncology-asco-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rapt-therapeutics-announces-flx475-poster-presentation-at-the-2023-american-society-of-clinical-oncology-asco-annual-meeting\\\/\",\"name\":\"RAPT Therapeutics Announces FLX475 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rapt-therapeutics-announces-flx475-poster-presentation-at-the-2023-american-society-of-clinical-oncology-asco-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rapt-therapeutics-announces-flx475-poster-presentation-at-the-2023-american-society-of-clinical-oncology-asco-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNjU0MyM1NTYwMDY2IzIwMjkyMDk=\",\"datePublished\":\"2023-04-26T22:16:51+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rapt-therapeutics-announces-flx475-poster-presentation-at-the-2023-american-society-of-clinical-oncology-asco-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rapt-therapeutics-announces-flx475-poster-presentation-at-the-2023-american-society-of-clinical-oncology-asco-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rapt-therapeutics-announces-flx475-poster-presentation-at-the-2023-american-society-of-clinical-oncology-asco-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNjU0MyM1NTYwMDY2IzIwMjkyMDk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNjU0MyM1NTYwMDY2IzIwMjkyMDk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rapt-therapeutics-announces-flx475-poster-presentation-at-the-2023-american-society-of-clinical-oncology-asco-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"RAPT Therapeutics Announces FLX475 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"RAPT Therapeutics Announces FLX475 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/rapt-therapeutics-announces-flx475-poster-presentation-at-the-2023-american-society-of-clinical-oncology-asco-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"RAPT Therapeutics Announces FLX475 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting - Market Newsdesk","og_description":"SOUTH SAN FRANCISCO, Calif., April 26, 2023 (GLOBE NEWSWIRE) &#8212; RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced it will present a poster on FLX475, its lead oncology drug candidate, at the 2023 American Society of Clinical Oncology (ASCO) annual meeting taking place June 2-6, 2023 at the McCormick Place Convention Center in Chicago, IL. Presentation details: Title: Clinical and Biological Activity of FLX475, an Oral CCR4 Antagonist, in Advanced Cancer Session Title: Developmental Therapeutics\u2014Immunotherapy Session Date and Time: Saturday, June 3, 2023; 8:00 a.m. &#8211; 11:00 a.m. ET Abstract Number: 2625 The abstract will &hellip; Continue reading \"RAPT Therapeutics Announces FLX475 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/rapt-therapeutics-announces-flx475-poster-presentation-at-the-2023-american-society-of-clinical-oncology-asco-annual-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2023-04-26T22:16:51+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNjU0MyM1NTYwMDY2IzIwMjkyMDk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rapt-therapeutics-announces-flx475-poster-presentation-at-the-2023-american-society-of-clinical-oncology-asco-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rapt-therapeutics-announces-flx475-poster-presentation-at-the-2023-american-society-of-clinical-oncology-asco-annual-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"RAPT Therapeutics Announces FLX475 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting","datePublished":"2023-04-26T22:16:51+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rapt-therapeutics-announces-flx475-poster-presentation-at-the-2023-american-society-of-clinical-oncology-asco-annual-meeting\/"},"wordCount":260,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rapt-therapeutics-announces-flx475-poster-presentation-at-the-2023-american-society-of-clinical-oncology-asco-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNjU0MyM1NTYwMDY2IzIwMjkyMDk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rapt-therapeutics-announces-flx475-poster-presentation-at-the-2023-american-society-of-clinical-oncology-asco-annual-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/rapt-therapeutics-announces-flx475-poster-presentation-at-the-2023-american-society-of-clinical-oncology-asco-annual-meeting\/","name":"RAPT Therapeutics Announces FLX475 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rapt-therapeutics-announces-flx475-poster-presentation-at-the-2023-american-society-of-clinical-oncology-asco-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rapt-therapeutics-announces-flx475-poster-presentation-at-the-2023-american-society-of-clinical-oncology-asco-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNjU0MyM1NTYwMDY2IzIwMjkyMDk=","datePublished":"2023-04-26T22:16:51+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rapt-therapeutics-announces-flx475-poster-presentation-at-the-2023-american-society-of-clinical-oncology-asco-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/rapt-therapeutics-announces-flx475-poster-presentation-at-the-2023-american-society-of-clinical-oncology-asco-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rapt-therapeutics-announces-flx475-poster-presentation-at-the-2023-american-society-of-clinical-oncology-asco-annual-meeting\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNjU0MyM1NTYwMDY2IzIwMjkyMDk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNjU0MyM1NTYwMDY2IzIwMjkyMDk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rapt-therapeutics-announces-flx475-poster-presentation-at-the-2023-american-society-of-clinical-oncology-asco-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"RAPT Therapeutics Announces FLX475 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/751720","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=751720"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/751720\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=751720"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=751720"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=751720"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}